SARcode Bioscience Inks $44M Series B
Brisbane, Calif.-based SARcode Bioscience has closed on $44 million in Series B financing, led by Sofinnova Ventures. Rho Ventures also participated, as did existing investors Alta Partners and Clarus Venture Partners. The money will go toward clinical development of the company’s treatment for dry eye syndrome.
18 July 2011•4 mins read
